Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors May 10, 2023
POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of metastatic CRPC May 10, 2023
European Commission granted approval to AKEEGA® (Niraparib & Abiraterone Dual Action Tablet) for the Treatment of Patients with metastatic CRPC with BRCA1/2 Mutations May 10, 2023
ESSA Pharma and Janssen to evaluate EPI-7386 in combination with apalutamide and abiraterone acetate plus prednisone in patients with prostate cancer April 20, 2023
Ph 1/2 clinical trials of GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients discontinued March 31, 2023
Ph 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer March 31, 2023
Update provided on US Regulatory Review of LYNPARZA + Abiraterone in metastatic CRPC patients March 15, 2023
Fusion Pharmaceuticals To Acquire Ph 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting metastatic CRPC February 22, 2023
Updated Data Demonstrating Improved Outcomes from Niraparib + Abiraterone + Prednisone in 1L BRCA+ve metastatic CRPC announced February 22, 2023
Positive TALZENNA® and XTANDI® Combination Data from Ph 3 TALAPRO-2 Study Announced February 22, 2023
Final Results of Key Secondary OS Endpoint From Phase 3 PROpel Trial presented, OS endpoint not met February 22, 2023
KEYNOTE-991 Trial Evaluating KEYTRUDA® Plus Enzalutamide and Androgen Deprivation Therapy in Patients With mHSPC to Stop for Futility February 1, 2023
Enrollment in Ph 1 Trial of ADXS-504 for the Treatment of Early Prostate cancer completed January 17, 2023
Positive Top-line Results from Pivotal Ph 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer Announced January 11, 2023
Lynparza + abiraterone approved in the EU in 1L metastatic CRPC based on Ph 3 PROpel trial results January 4, 2023
PDUFA date extended by three months to review Lynparza + abiraterone & prednisone supplemental NDA for metastatic CRPC December 19, 2022
European Commission Approves Pluvicto® For Treatment Of Progressive PSMA+ve metastatic CRPC December 19, 2022
Pluvicto™ shows statistically significant & clinically meaningful rPFS benefit in patients with PSMA+ve metastatic CRPC December 12, 2022
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 November 23, 2022
Lynparza – abiraterone combo recommended for approval in the EU by CHMP in 1L metastatic CRPC November 23, 2022
